anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Androgenic alopecia (AGA) is the most common type of alopecia and its treatments involve drugs that have various adverse effects and are not completely effective. Radiofrequency-based therapies (RF) are an alternative for AGA treatment. Although there is increasing clinical evidence of the effectiveness of RF for alopecia, its effects at the tissue and cellular level have not been studied in detail. The objective of this study was to analyze ex vivo the potential effect of RF currents used in capacitive resistive electrical transfer (CRET) therapy on AGA. Hair follicles (HFs) were donated by patients with AGA and treated with CRET. AGA-HFs were exposed in vitro to intermittent 448 kHz electric current in subthermal conditions. Cell proliferation (Ki67), apoptosis (TUNEL assay), differentiation (β-catenin), integrity (collagen and MMP9), thickness of the epidermis surrounding HF, proportion of bulge cells and melanoblasts in AGA-HF were analyzed by immunohistochemistry. CRET increased proliferation and decreased death of different populations of AGA-HF cells. In addition, the melanoblasts increased in bulge and the epidermis surrounding the hair follicle thickened. These results support the effectiveness of RF-based therapies for the treatment of alopecia. However, clinical trials are necessary to know the true effectiveness of CRET therapy and other RF therapies for AGA treatment.
Firefighters and emergency medical technicians (EMTs)/ paramedics respond to more than 50 million emergency calls in the U.S. every year. The daily operations and experiences that are expected and accepted as part of their job expose them to various traumatic events. The nature, frequency, and intensity of duty-related traumatic exposures place these first responders (FRs) at significant risk for mental health (MH) problems, such as post-traumatic stress disorder (PTSD) and suicide. However, due to the stigma of mental illness and the culture of self-reliance and strength that surrounds FRs, few are willing to seek help. There will be a two-stage exploratory, qualitative study that will use a statewide community-engagement approach to conceptualize a MH service model that would motivate FRs to be more engaged in services. In Stage 1, qualitative interviews with firefighters and EMTs/ paramedics will be conducted across Arkansas. In Stage 2, product development process grounded in these findings to conceptualize a MH service model feasible for implementation in real world settings. (Protocol for Stage 2 will be submitted for IRB approval at a later time.) Stage 1, Specific Aim: Identify FRs' preferences and priorities regarding MH service and delivery methods, including the feasibility, acceptability, and value of each method. To address this aim, we will use opt-in methods to recruit a diverse group of firefighters and EMTs/paramedics from across Arkansas to participate in qualitative interviews, defined as focus groups and individual interviews. After all qualitative interviews have been analyzed, a series of product development activities in Stage 2. Through this work, the scientific foundation to develop a comprehensive, MH service model that will motivate engagement in services by diverse FRs. This study's findings will guide a multi-stage, research agenda that will include development and pilot testing of the MH service model, ultimately, promoting engagement in MH services may decrease suicide rates and improve the overall MH outcomes among this at-risk population.
The parent intervention group will undergo 8 weekly, manualized group sessions, with between 6 and 10 parent participants. Sessions are structured and follow an agenda including check-in and review of home practice, discussion of a skill or strategy, and review and assignment of home practice. Group sessions are held weekly for 1.5 hours and include both didactic, discussion, and practice elements, as well as assigned home practice.
There are few effective treatments for recurrent aphthous stomatitis (cancer sores, recurrent mouth ulcers). Most existing treatments are palliative topical treatments. Some systemic drugs e.g. steroids and thalidomide can suppress the recurrence of mouth ulcers but have serious long term side effects. Pentoxifylline (also known as oxpentifylline) has been used systemically for many years to treat peripheral vascular disease and has a good side effect profile. It shares several actions with thalidomide but does not share its serious side effects. Furthermore, some small scale, open label clinical studies have indicated it may be very effective in treating recurrent aphthous stomatitis (RAS). This study enrolled patients with RAS for which no underlying cause could be identified. Patients kept a diary of the pattern of their mouth ulcers for 60 days to confirm the pattern of ulceration and provide baseline data. Those still qualified for the study were then randomized to treatment with pentoxifylline 400mg three times daily or an identical placebo tablet three times daily for a further 60 days during which they continued to keep a daily ulcer diary. At the end of this period, treatment was stopped and they kept the daily ulcer diary for a further 60 days to identify if any benefit from the treatment was continued after ceasing treatment.
FIELD: cosmetic industry. SUBSTANCE: biologically active additive is larvas of bee drones (drone brood). Cream based on additive contains ground insects larva, biologically active substances of vegetable and animal origin. The components are used in the following ratio, mas.%: bee drones larvas (drone brood), 0.5-3.5; biologically active substances of vegetable and animal origin including vegetable oils and bacteriostatic additives, or vegetable oils, bacteriostatic and tonic additives, or vegetable oils, bacteriostatic and calming additives, not more 24.0; base, the balance. EFFECT: higher nourishing and regenerating action. 3 cl
Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
Type 2 Diabetes - Adults (see Table 5)

One six-month, open-label, active-controlled study was conducted to compare the safety and efficacy of NOVOLOG to regular human insulin in patients with type 2 diabetes (Table 5). 

The mean age of the trial population was 56.6 years and mean duration of diabetes was 12.7 years. Sixty-three percent were male. Seventy-six percent were Caucasian, 9% were Black and 15% were Other. The mean BMI was approximately 29.7 kg/m2. 

NOVOLOG was administered by subcutaneous injection immediately prior to meals and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily doses. Changes in HbA1c were comparable for the two treatment regimens.

Table 5. Subcutaneous NOVOLOG Administration in Type 2 Diabetes (6 months; n=176)

*Values are Mean ± SD
PROBLEM TO BE SOLVED: To obtain an ultraviolet protectant which is easily available, highly safe, and highly effective by pulverizing tourmaline or garnet. SOLUTION: An ultraviolet-protecting cosmetic is obtained by uniformly adding a small amount of the protectant to the base of a cosmetic applied to the skin. A cosmetic having a wider range of wavelengths of ultraviolet rays to be cut can be obtained by further adding a small amount of phenyl salicylate or cinoxate. A plastic film for ultraviolet protection is obtained by adding a small amount of the protectant to a melt of a plastic base material. A fiber for ultraviolet protection is obtained by adding a small amount of the protectant to a synthetic or natural fiber base material. A fiber base material having a wider range of wavelengths of ultraviolet rays to be cut is obtained by adding a small amount of phenyl salicylate or cinoxate to the fiber. This fiber is processed to obtain a woven or nonwoven cloth for ultraviolet protection.
Methods of prophylactic and therapeutic immunization of an individual against pathogen infection, diseases associated with hyperproliferative cells and autoimmune diseases are disclosed. The methods comprise the steps of administering to cells of an individual, a nucleic acid molecule that comprises a nucleotide sequence that encodes a protein which comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen, a hyperproliferative cell associated protein or a protein associated with autoimmune disease respectively. In each case, nucleotide sequence is operably linked to regulatory sequences to enable expression in the cells. The nucleic acid molecule is free of viral particles and capable of being, expressed in said cells. The cells may be contacted cells with a cell stimulating agent. Methods of prophylactically and therapeutically immunizing an individual against HIV are disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.
The invention provides MRI detectable species of formula (I) Dp-Sn-Nm wherein D is a MRI detectable moiety S is a spacer N is a molecule of a nutrient or pseudo-nutrient n is 0 or an integer m is an integer and p is an integer. <??>These compounds are useful for internalising into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalised in normal healthy cells thus allowing the diagnosis of tumors. <??>Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion. In this case when the paramagnetic metal ion is a neutron capture isotope, e.g. <157>Gd, the new compounds can also be used for the treatment of the tumor, by selective irradiation of the tumor mass.
The invention discloses a method for extraction of bio-flavonoid. The method utilizes a supercritical carbon dioxide fluid to extract bio-flavonoid from Abelmoschus manihot seeds. Before extraction, Abelmoschus manihot seeds are subjected to pre-drying and crushing and the powder is dried and cooled, and in extraction, an extraction temperature is 50 DEG C, pressure is in a range of 25-30MPa, a flow amount of carbon dioxide gas going through an extraction kettle is in a range of 100-160kg/h and extraction time is 2h. A carbon dioxide fluid in a supercritical state is used as an extraction solvent. The extraction solvent is recycled in the same system, solvent consumption is low, a price is low, an extraction cost is low and an extraction period is short and is in a range of 2-3h. The extracted bio-flavonoid has the characteristics of good quality, high purity, no peculiar smell, no solvent residue and no environmental pollution. The method has simple processes and low energy consumption.
Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. Now the inventors showed the expression of CD38 by Sézary cells and in CD4+ blood cells of patients with Sezary syndrome. CD38 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CD38-expressing cancer cells would eliminate tumor cells.
Patients participate in 4 weekly TAB in-person or video conference sessions over 1 hour each that provide them with skills to cope with their dyspnea. Patients also receive treatment handouts, a CD with an audio file with instructions for progressive muscle relaxation, and a pulse oximeter. Patients may receive additional support calls over 10-15 minutes from the TAB provider within 1 week following each session.
NEW MATERIAL:The TFS-1 antibody (immunoglobulin G2a-class recognizing the antigen having a molecular weight of about 42 k-Dalton in reduced state and having complement-dependent cytotoxic activity), TFS-2 antibody, TFS-3 antibody and TFS-4 antibody. USE:An antibody for human plumonary cancer cell. It is effective to kill the cells of plumonary small cell cancer mixed in normal cells such as blood cells including lymphatic system, without giving harmful effect to the normal cells. PREPARATION:Mouse is sensitized with TNSC-1 and TNSC-2 which are strains of human plumonary small cell cancer, and the spleen is extracted from the mouse. The spleen cell is mixed with the myeloma cell of the mouse of the same species, and fused together. The obtained hybridoma (e.g. mouse hybridoma ADH1-79, etc.) is cultured, the produced monoclonal antibody is made to react with various human carcinoma cell strains and normal cells, and the objective TFS-1 antibody, etc. is produced e.g. by radio-immunoassay.
Novel cytotoxic agent useful against malignant tumors. It provides a stable composition of matter based on the cytotoxic activity of two synergistically acting toxins which sequence are herein described. The basic amphipathic peptide binds to the cell membrane causing perturbation of the lipid bilayer. The non-covalent heterodimer complex dissociates and the phospholiphase A 2  subunit (B) binds to the cell membrane. Subunit A acts as a chaperon preventing non-specific binding of the phospholipase A 2 , it has no enzymatic activity. The basic amphipathic peptide increases the effect of the phospholipase A 2  subunit. Cell death is caused by the enzymatic hydrolysis of cell membrance phospholipids. Both the non-covalent heterodimer complex and the basic amphipathic peptide used were purified from the venoms of Crotalus durissus terrificus and Naja naja atra, respectively.
Participants receive pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle (Q3W) for a maximum of 10 cycles (approximately 7 months). Participants also concomitantly receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each 21-day docetaxel cycle.
Glimepiride did not produce teratogenic effects in rats exposed orally up to 4000 mg/kg body weight (approximately 4,000 times the maximum recommended human dose based on surface area) or in rabbits exposed up to 32 mg/kg body weight (approximately 60 times the maximum recommended human dose based on surface area). Glimepiride has been shown to be associated with intrauterine fetal death in rats when given in doses as low as 50 times the human dose based on surface area and in rabbits when given in doses as low as 0.1 times the human dose based on surface area. This fetotoxicity, observed only at doses inducing maternal hypoglycemia, has been similarly noted with other sulfonylureas, and is believed to be directly related to the pharmacologic (hypoglycemic) action of glimepiride. 

There are no adequate and well-controlled studies in pregnant women. On the basis of results from animal studies, glimepiride tablets should not be used during pregnancy. Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain glucose levels as close to normal as possible.
UNLABELLED: TFE3 is a member of the basic helix-loop-helix leucine zipper MiT transcription factor family, and its chimeric proteins are associated with translocation renal cell carcinoma (tRCC). Despite the variety of gene fusions, most TFE3 fusion partner genes are related to spliceosome machinery. Dissecting the function of TFE3 fused to spliceosome machinery factors (TFE3-SF) could direct the development of effective therapies for this lethal disease, which is refractory to standard treatments for kidney cancer. Here, by using a combination of in silico structure prediction, transcriptome profiling, molecular characterization, and high-throughput high-content screening (HTHCS), we interrogated a number of oncogenic mechanisms of TFE3-SF fusions. TFE3-SF fusions drove the transformation of kidney cells and promoted distinct oncogenic phenotypes in a fusion partner-dependent manner, differentially altering the transcriptome and RNA splicing landscape and activating different oncogenic pathways. Inhibiting TFE3-SF dimerization reversed its oncogenic activity and represented a potential target for therapeutic intervention. Screening the FDA-approved drugs library LOPAC and a small-molecule library (Microsource) using HTHCS combined with FRET technology identified compounds that inhibit TFE3-SF dimerization. Hit compounds were validated in 2D and 3D patient-derived xenograft models expressing TFE3-SF. The antihistamine terfenadine decreased cell proliferation and reduced in vivo tumor growth of tRCC. Overall, these results unmask therapeutic strategies to target TFE3-SF dimerization for treating patients with tRCC.
SIGNIFICANCE: TFE3-splicing factor fusions possess both transcription and splicing factor functions that remodel the transcriptome and spliceosome and can be targeted with dimerization inhibitors to suppress the growth of translocation renal cell carcinoma.
PURPOSE: Trial data shows modest reductions in leg pain, disability and surgery avoidance following epidural steroid injections (ESI) for severe sciatica. Despite their common use, there is no clear evidence about which patients are more likely to benefit from ESI. The aim of this study was to generate consensus on potential predictors of outcome following ESI for disc-related sciatica.
METHODS: A list of potential predictors of outcome was generated during a consensus meeting of seven experts. The items were subsequently presented in a two round on-line Delphi study to generate consensus among experts on which items are potential predictors of outcome. Consensus was defined as 70% agreement among participants.
RESULTS: Sixty-one items were generated during the consensus meeting. Of ninety experts invited to participate in the on-line Delphi study, 44 (48%) and 33 (73%) took part in rounds one and two respectively. Twenty-eight additional items suggested by participants in round one were included in round two. Overall, 14 items reached consensus reflecting domains of health, medication use, pain intensity, psychosocial factors, imaging findings and type of injection.
CONCLUSION: Based on expert consensus, items that can be routinely collected in clinical practice were identified as potential predictors of outcomes following ESI.
BACKGROUND: Predicting disease progression in patients with the first clinical episode suggestive of multiple sclerosis (MS) is crucial for personalized therapeutic approaches. This study aimed to develop the EUMUS score for accurately estimating the risk of early evidence of disease activity and progression (EDA).
METHODS: Retrospective analysis was conducted on data from 221 patients with a first clinical MS episode collected from four Italian MS centers. Various variables including socio-demographics, clinical features, cerebrospinal fluid analysis, evoked potentials, and brain MRI were considered. A prognostic multivariate regression model was identified to develop the EUMUS score. The optimal cutoff for predicting the transition from no evidence of disease activity (NEDA3) to EDA was determined. The accuracy of the prognostic model and score were tested in a separate UK MS cohort.
RESULTS: After 12 months, 61.54% of patients experienced relapses and/or new MRI lesions. Younger age (OR 0.96, CI 0.93-0.99; p = 0.005), MRI infratentorial lesion(s) at baseline (OR 2.21, CI 1.27-3.87; p = 0.005), positive oligoclonal bands (OR 2.89, CI 1.47-5.69; p = 0.002), and abnormal lower limb somatosensory-evoked potentials (OR 2.77, CI 1.41-5.42; p = 0.003) were significantly associated with increased risk of EDA. The EUMUS score demonstrated good specificity (72%) and correctly classified 80% of patients with EDA in the independent UK cohort.
CONCLUSIONS: The EUMUS score is a simple and useful tool for predicting MS evolution within 12 months of the first clinical episode. It has the potential to guide personalized therapeutic approaches and aid in clinical decision-making.
BACKGROUND AND AIMS: Postoperative stricture is a serious common adverse event after extensive endoscopic submucosal dissection (ESD) in the esophagus. Self-assembling peptide (SAP) gel has been shown to promote tissue healing and re-epithelialization. The aim of this study was to evaluate the effect of the SAP gel for esophageal stricture prevention after ESD.
METHODS: This was a multicenter prospective study of patients who underwent esophageal ESD followed by SAP gel application between March 2022 and December 2023. Patients were included if the ESD mucosal defect involved ≥50% of the circumference of the esophagus. High-risk cases were defined as mucosal defects ≥75% of the circumference. Stricture was defined as the inability to pass an endoscope ≥8.9 mm in diameter or a narrow-caliber lumen in a patient with symptoms.
RESULTS: A total of 43 patients (median age, 71 years; 81.4% male) underwent ESD (median resected specimen size, 50 mm) during the study period. SAP gel (median, 3 mL) was successfully applied in all cases (median time, 4 minutes). In aggregate, stricture occurred in 20.9% (9 of 43) of the cases. Stricture developed in 30.8% of the high-risk cases: 80% (4 of 5) after circumferential ESD and 19% (4 of 21) in those with defects ≥75% but <100% of the circumference. All cases of stricture resolved with endoscopic treatment. Three cases (6.9%) of postoperative bleeding occurred and were adequately managed endoscopically.
CONCLUSIONS: We show that SAP gel application was easy, quick, and associated with a relatively low stricture rate comparable to other prophylactic methods. Additional comparative studies are needed to corroborate these preliminary findings.
BACKGROUND: Patients with atrial fibrillation (AF) and intracerebral hemorrhage (ICH) are at high risk of ischemic and recurrent bleeding events. Therefore, the decision of restarting or avoiding anticoagulation is challenging. Left atrial appendage occlusion (LAAO) is an alternative for these patients. However, few data are available about safety of early LAAO and factors associated with ischemic stroke and ICH recurrence.
METHODS: A unicentric, observational, retrospective study including all patients with AF and a previous ICH who underwent LAAO. We analyzed baseline clinical and neuroimaging characteristics, procedural outcomes, post-procedural therapies and long-term follow-up.
RESULTS: Forty patients were included, whose mean age was 76.6 ±7.6 years and 73 % were men. In patients in whom a Magnetic Resonance (MR) was performed (n=22, 55 %), cortical microbleeds were detected in 15 (68 %) and cortical superficial siderosis in one patient. The procedure was successful and safe in 100 % of the patients and it was performed within 30 days of the ICH in 37 % of them. After a median follow up of 46.2 months [26-69], intracranial hemorrhage (ICrH) recurrence occurred in 6 patients (5 ICH and 1 subdural hematoma -SDH-) and the index ICH was lobar in all of them. Ischemic events were significantly lower than expected according to the CHA2DS2-VASc score (7.5 % vs. 16.6 %, p=0.048) and bleeding events were similar to expected by the HAS-BLED score (20 % vs 23.4 %, p=0.63).
CONCLUSIONS: In patients with ICH and AF, early LAAO was found to be safe and associated with a reduction in ischemic stroke. However, recurrent ICH risk remains high, and it appears to be mainly driven by cerebral amyloid angiopathy.